Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: oldcoach19 who wrote (1875)	4/22/2016 5:43:38 PM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

OC, who is MK? The statement that "no additional clinical studies expected" for FDA consideration of Vitaros was not raised by me, it has been made by the company repeatedly in conference calls and most recently on page 14 of the latest company powerpoint presentation. That is as firm a statement as I have seen a company make about information needs by the FDA. The current share price will give any investor pause, including me. Again my thinking is that the devastating drop reflects the failure of Fis. Clinical trial failures happen and are the bane of biotechs, large and small. I like the fact that the company has limited debt, has tightened its belt, and that Vitaros has been approved by Europe with a track record of many men using it along with the company's strong statement about no additional clinical studies expected by the FDA. I share your frustrations bigtime as almost all my shares were purchased when Damaj still was chair and ceo. However, at these prices I will very likely purchase more shares next week as my order did not fill today. I am hoping that MI's assessment is correct, that the company will survive any delisting drama. But we will see. James